Cost-efficiency analysis and expanded treatment access modeling of conversion to rituximab biosimilars from reference rituximab in Jordan-Reference-Cited by-同舟云学术

Cost-efficiency analysis and expanded treatment access modeling of conversion to rituximab biosimilars from reference rituximab in Jordan

Published:2023-06-30 Issue:1 Volume:26 Page:835-842
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Halawah Hala H.¹^ORCID,Alkhatib Nimer S.¹²³^ORCID,Almutairi Abdulaali R.⁴^ORCID,Saleh Mohammad¹⁵^ORCID,Halloush Shiraz S.⁶^ORCID,Rashdan Omar⁷^ORCID,Masadh Lama⁸,Abusara Osama H.¹^ORCID,Abraham Ivo²⁹¹⁰^ORCID

Affiliation:

1. Al-Zaytoonah University of Jordan, Amman, Jordan

2. Center for Health Outcomes and PharmacoEconomic Research, University of Arizon, Tucson, AZ, USA

3. PI Pharma Intelligence, Amman, Jordan

4. Saudi Food and Drug Authority, Riyadh, Saudi Arabia

5. School of Pharmacy, University of Jordan, Amman, Jordan

6. Applied Science Private University, Amman, Jordan

7. School of Pharmacy, Middle East University, Amman, Jordan

8. Ministry of Health, Amman, Jordan

9. University of Arizona Cancer Center, University of Arizona, Tucson, AZ, USA

10. Matrix45, Tucson, AZ, USA

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2023.2226007

Reference26 articles.

1. Food and Drug Administration. FDA approves first biosimilar for treatment of adult patients with non-Hodgkin’s lymphoma. [cited 2022 Oct 27]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-biosimilar-treatment-adult-patients-non-hodgkins-lymphoma.

2. A molecular perspective on rituximab: A monoclonal antibody for B cell non Hodgkin lymphoma and other affections

3. Comparative cost efficiency across the European G5 countries of originators and a biosimilar erythropoiesis-stimulating agent to manage chemotherapy-induced anemia in patients with cancer

4. Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia

5. Cost savings from anemia management with biosimilar epoetin alfa and increased access to targeted antineoplastic treatment: a simulation for the EU G5 countries

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. What to expect in 2024: important health economics and outcomes research (HEOR) trends;Expert Review of Pharmacoeconomics & Outcomes Research;2023-12-21

2. What to expect in 2024: important health economics and outcomes research (HEOR) trends;Journal of Medical Economics;2023-12-20

3. What to expect in 2024: important health economics and outcomes research (HEOR) trends;Current Medical Research and Opinion;2023-12-20

4. What to Expect in 2024: Important Health Economics and Outcomes Research (HEOR) Trends;ClinicoEconomics and Outcomes Research;2023-12

5. Preparing for the third decade of biosimilars;Expert Opinion on Biological Therapy;2023-08-03